Scisparc: Ethics Committee OKs Phase IIb Trial In Tourette

 SciSparc Ltd. 

SPRC-13.8%+ Free Alerts

 ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it received Ethics Committee approvals from Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel, to conduct the Company’s Phase IIb clinical study for SCI-110 in patients suffering from Tourette Syndrome ("TS"). The Company is evaluating additional clinical sites to join the Phase 2b trial to expedite patient enrollment in a timely manner.

https://www.benzinga.com/general/biotech/22/05/27415847/scisparc-announces-ethics-committee-approval-to-conduct-a-phase-iib-trial-in-tourette-syndrome